Associations between severe pulmonary function and residual CT abnormalities in rehabilitating COVID-19 patients
OBJECTIVE: Coronavirus disease 2019 (COVID-19) spread around the world in 2020. Abnormal pulmonary function and residual CT abnormalities were observed in COVID-19 patients during recovery. Appropriate rehabilitation training is around the corner. The correlation between spirometric impairment and residual CT abnormality remains largely unknown.
PATIENTS AND METHODS: A cross-sectional study conducted on the pulmonary function of 101 convalescent COVID-19 patients before discharge. Multivariate analysis was used to establish a scoring system to evaluate the spirometric abnormality based on residual chest CT.
RESULTS: Lung consolidation area >25% and severe-type COVID-19 were two independent risk factors for severe pulmonary dysfunction. Besides, a scoring system was established. People scoring more than 12 points have more chances (17 times) to get severe pulmonary function impairment before discharge.
CONCLUSIONS: For the first time, a chest CT characteristics-based grading system was suggested to predict the pulmonary dysfunction of COVID-19 patients during convalescence in this study. This study may provide suggestions for pulmonary rehabilitation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
---|---|
Enthalten in: |
European review for medical and pharmacological sciences - 25(2021), 23 vom: 17. Dez., Seite 7585-7597 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Yu, C [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 05.01.2022 Date Revised 05.01.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.26355/eurrev_202112_27457 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM334554195 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM334554195 | ||
003 | DE-627 | ||
005 | 20231225223942.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.26355/eurrev_202112_27457 |2 doi | |
028 | 5 | 2 | |a pubmed24n1115.xml |
035 | |a (DE-627)NLM334554195 | ||
035 | |a (NLM)34919259 | ||
035 | |a (PII)27457 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Yu, C |e verfasserin |4 aut | |
245 | 1 | 0 | |a Associations between severe pulmonary function and residual CT abnormalities in rehabilitating COVID-19 patients |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 05.01.2022 | ||
500 | |a Date Revised 05.01.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a OBJECTIVE: Coronavirus disease 2019 (COVID-19) spread around the world in 2020. Abnormal pulmonary function and residual CT abnormalities were observed in COVID-19 patients during recovery. Appropriate rehabilitation training is around the corner. The correlation between spirometric impairment and residual CT abnormality remains largely unknown | ||
520 | |a PATIENTS AND METHODS: A cross-sectional study conducted on the pulmonary function of 101 convalescent COVID-19 patients before discharge. Multivariate analysis was used to establish a scoring system to evaluate the spirometric abnormality based on residual chest CT | ||
520 | |a RESULTS: Lung consolidation area >25% and severe-type COVID-19 were two independent risk factors for severe pulmonary dysfunction. Besides, a scoring system was established. People scoring more than 12 points have more chances (17 times) to get severe pulmonary function impairment before discharge | ||
520 | |a CONCLUSIONS: For the first time, a chest CT characteristics-based grading system was suggested to predict the pulmonary dysfunction of COVID-19 patients during convalescence in this study. This study may provide suggestions for pulmonary rehabilitation | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
700 | 1 | |a Hu, X-Y |e verfasserin |4 aut | |
700 | 1 | |a Zou, C |e verfasserin |4 aut | |
700 | 1 | |a Yu, F-F |e verfasserin |4 aut | |
700 | 1 | |a Liu, B |e verfasserin |4 aut | |
700 | 1 | |a Li, Y |e verfasserin |4 aut | |
700 | 1 | |a Liu, Y |e verfasserin |4 aut | |
700 | 1 | |a Song, L-J |e verfasserin |4 aut | |
700 | 1 | |a Tan, L |e verfasserin |4 aut | |
700 | 1 | |a Li, Q |e verfasserin |4 aut | |
700 | 1 | |a Hu, Y-C |e verfasserin |4 aut | |
700 | 1 | |a He, H-Y |e verfasserin |4 aut | |
700 | 1 | |a Chen, M-Y |e verfasserin |4 aut | |
700 | 1 | |a Zou, Z |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European review for medical and pharmacological sciences |d 1997 |g 25(2021), 23 vom: 17. Dez., Seite 7585-7597 |w (DE-627)NLM09387944X |x 2284-0729 |7 nnns |
773 | 1 | 8 | |g volume:25 |g year:2021 |g number:23 |g day:17 |g month:12 |g pages:7585-7597 |
856 | 4 | 0 | |u http://dx.doi.org/10.26355/eurrev_202112_27457 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 25 |j 2021 |e 23 |b 17 |c 12 |h 7585-7597 |